LobbyingJerome Stevens Pharmaceuticals lobbying by quarter
Jerome Stevens Pharmaceuticals's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $150K. Its first report covers Q2 2024; the issues it reports most are Medicare/Medicaid.
Jerome Stevens Pharmaceuticals
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $150K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2024 | $20K | 1 |
| Q3 2024 | $50K | 1 |
| Q4 2024 | $50K | 1 |
| Q1 2025 | $50K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $50K | 1 |
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Medicare and Medicaid$420K · 9 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES9 reports
- SENATE9 reports
Firms it paid
| Firm | ||
|---|---|---|
| Alpine Group Partners | $420K | 9 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ERIN MENDELSOHN | LD, Rep. Anna Eshoo; Congressional Liaison - FDA | Q2 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/18for Q2 | Alpine Group Partners | $50K |
| 04/20for Q1 | Alpine Group Partners | $50K |
| 03/02for Q4 2024 | Alpine Group Partners | $50K |
| 01/16for Q4 2025 | Alpine Group Partners | $50K |
| 25/10/19for Q3 2025 | Alpine Group Partners | $50K |
| 25/07/21for Q2 2025 | Alpine Group Partners | $50K |
| 25/04/17for Q1 2025 | Alpine Group Partners | $50K |
| 25/01/19for Q4 2024 | Alpine Group Partners | $50K |
| 24/10/22for Q3 2024 | Alpine Group Partners | $50K |
| 24/07/22for Q2 2024 | Alpine Group Partners | $20K |
| 24/07/11for Q2 2024 | Alpine Group Partners | Under $5,000 |